Improving drug uptake and penetration into tumors: Current and forthcoming opportunities

Frontiers in Oncology

Volumn 3 JUN, Issue , 2013, Pages

  Marcucci, Fabrizio ^a,b   Berenson, Ronald ^c   Corti, Angelo ^d  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

^b Hepatology Association of Calabria   (Italy)

^c ImmunoMod Consulting   (United States)

^d SAN RAFFAELE HOSPITAL   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BEVACIZUMAB; IPILIMUMAB;

CELL INFILTRATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG PENETRATION; DRUG TUMOR LEVEL; EDITORIAL; EXTRACELLULAR MATRIX; HUMAN; IMMUNOCOMPETENT CELL; NEOPLASM; SOLID TUMOR; TUMOR VASCULARIZATION;

EID: 84891638533     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2013.00161     Document Type: Editorial

References (28)

1. Beyer, I., Cao, H., Persson, J., Song, H., Richter, M., Feng, Q., et al. (2012). Co-administration of epithelial junction opener JO-1 improves the efficacy and safety of chemotherapeutic drugs. Clin. Cancer Res. 18, 3340-3351. doi:10.1158/1078-0432.CCR-11-3213.
2. Beyer, I., van Rensburg, R., Strauss, R., Li, Z. Y., Wang, H., Persson, J., et al. (2011). Epithelial junction opener JO-1 improves monoclonal antibody therapy of cancer. Cancer Res. 71, 7080-7090. doi:10.1158/0008-5472.CAN-11-2009.
3. Calcinotto, A., Grioni, M., Jachetti, E., Curnis, F., Mondino, A., Parmiani, G., et al. (2012). Targeting TNF-α to neoangiogenic vessels enhances lymphocyte infiltration in tumors and increases the therapeutic potential of immunotherapy. J. Immunol. 188, 2687-2694. doi:10.4049/jimmunol.1101877.
4. Corti, A., and Marcucci, F. (1998). Tumour necrosis factor: strategies for improving the therapeutic index. J. Drug Target. 5, 403-413. doi:10.3109/10611869808997869.
5. Curnis, F., Sacchi, A., Borgna, L., Magni, F., Gasparri, A., and Corti, A. (2000). Enhancement of tumor necrosis factor α antitumor immunotherapeutic properties by targeted delivery to aminopeptidase N (CD13). Nat. Biotechnol. 18, 1185-1190. doi:10.1038/81183.
6. Curnis, F., Sacchi, A., and Corti, A. (2002). Improving chemotherapeutic drug penetration in tumors by vascular targeting and barrier alteration. J. Clin. Invest. 110, 475-482. doi:10.1172/JCI200215223.
7. Ganss, R., and Hanahan, D. (1998). Tumor microenvironment can restrict the effectiveness of activated antitumor lymphocytes. Cancer Res. 58, 4673-4681.
8. Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., et al. (2010). Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723. doi:10.1056/NEJMoa1003466.
9. Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., et al. (2004). Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med. 350, 2335-2342. doi:10.1056/NEJMoa032691.
10. Jain, R. K. (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307, 58-62. doi:10.1126/science.1104819.
11. Lynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., et al. (2012). Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J. Clin. Oncol. 30, 2046-2054. doi:10.1200/JCO.2011.38.4032.
12. Marcucci, F., Bellone, M., Rumio, C., and Corti, A. (2013). Approaches to improve tumor accumulation and interactions between monoclonal antibodies and immune cells. MAbs 5, 36-46. doi:10.4161/mabs.22775.
13. Marcucci, F., and Corti, A. (2012a). How to improve exposure of tumor cells to drugs-promoter drugs increase tumor uptake and penetration of effector drugs. Adv. Drug Deliv. Rev. 64, 53-68. doi:10.1016/j.addr.2011.09.007.
14. Marcucci, F., and Corti, A. (2012b). Improving drug penetration to curb tumor drug resistance. Drug Discov. Today 17, 1139-1147. doi:10.1016/j.drudis.2012.06.004.
15. Moschetta, M., Pretto, F., Berndt, A., Galler, K., Richter, P., Bassi, A., et al. (2012). Paclitaxel enhances therapeutic efficacy of the F8-IL2 immunocytokine to EDA-fibronectin-positive metastatic human melanoma xenografts. Cancer Res. 72, 1814-1824. doi:10.1158/0008-5472.CAN-11-1919.
16. Nagamitsu, A., Greish, K., and Maeda, H. (2009). Elevating blood pressure as a strategy to increase tumor-targeted delivery of macromolecular drug SMANCS: cases of advanced solid tumors. Jpn. J. Clin. Oncol. 39, 756-766. doi:10.1093/jjco/hyp074.
17. Padera, T. P., Stoll, B. R., Tooredman, J. B., Capen, D., di Tomaso, E., and Jain, R. K. (2004). Pathology: cancer cells compress intratumour vessels. Nature 427, 695. doi:10.1038/427695a.
18. Piali, L., Fichtel, A., Terpe, H.-J., Imhof, B. A., and Gisler, R. H. (1995). Endothelial vascular cell adhesion molecule 1 expression is suppressed by melanoma and carcinoma. J. Exp. Med. 181, 811-816. doi:10.1084/jem.181.2.811.
19. Provenzano, P. P., Cuevas, C., Chang, A. E., Goel, V. K., Von Hoff, D. D., and Hingorani, S. R. (2012). Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma. Cancer Cell 21, 418-429. doi:10.1016/j.ccr.2012.01.007.
20. Sacchi, A., Gasparri, A., Gallo-Stampino, C., Toma, S., Curnis, F., and Corti, A. (2006). Synergistic antitumor activity of cisplatin, paclitaxel, and gemcitabine with tumor vasculature-targeted tumor necrosis factor-α. Clin. Cancer Res. 2, 175-182. doi:10.1158/1078-0432.CCR-05-1147.
21. Sen, A., Capitano, M. L., Spernyak, J. A., Schueckler, J. T., Thomas, S., Singh, A. K., et al. (2011). Mild elevation of body temperature reduces tumor interstitial fluid pressure and hypoxia and enhances efficacy of radiotherapy in murine tumor models. Cancer Res. 71, 3872-3880. doi:10.1158/0008-5472.CAN-10-4482.
22. Springer, T. A. (1994). Traffic signals for lymphocyte recirculation and leukocyte emigration: the multistep paradigm. Cell 76, 301-314. doi:10.1016/0092-8674(94)90337-9.
23. Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., et al. (2012). Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med. 366, 2443-2454. doi:10.1056/NEJMoa1200690.
24. Trédan, O., Galmarini, C. M., Patel, K., and Tannock, I. F. (2007). Drug resistance and the solid tumor microenvironment. J. Natl. Cancer Inst. 99, 1441-1454. doi:10.1093/jnci/djm135.
25. Van der Veldt, A. A. M., Lubberink, M., Bahce, I., Walraven, M., de Boer, M. P., Greuter, H. N. J. M., et al. (2012). Rapid decrease in delivery of chemotherapy to tumors after anti-VEGF therapy: implications for scheduling of anti-angiogenic drugs. Cancer Cell 21, 82-91. doi:10.1016/j.ccr.2011.11.023.
26. Wang, H., Li, Z.-Y., Liu, Y., Persson, J., Beyer, I., Möller, T., et al. (2011). Desmoglein 2 is a receptor for adenovirus serotypes 3, 7, 11 and 14. Nat. Med. 17, 96-105. doi:10.1038/nm.2270.
27. Watson, K. D., Lai, C.-Y., Qin, S., Kruse, D. E., Lin, Y.-C., Seo, J. W., et al. (2012). Ultrasound increases nanoparticle delivery by reducing intratumoral pressure and increasing transport in epithelial and epithelial-mesenchymal transition tumors. Cancer Res. 72, 1485-1493. doi:10.1158/0008-5472.CAN-11-3232.
28. Willett, C. G., Boucher, Y., di Tomaso, E., Duda, D. G., Munn, L. L., Tong, R. T., et al. (2004). Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat. Med. 10, 145-147. doi:10.1038/nm988.